Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

United States

Market Cap

USD 20.12 B

Share Price

USD 105.90

Avg Daily Volume

2,289,787

Change (1 day)

0.46%

Change (1 year)

54.76%

Change (YTD)

53.39%

Insmed Incorporated Revenue Year-on-Year (YoY) growth for the Trailing 12 Months (TTM) ending March 31, 2025: 20.77%

Insmed Incorporated Revenue Year-on-Year (YoY) growth is 20.77% for the Trailing 12 Months (TTM) ending March 31, 2025. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period. Year-on-Year (YoY) growth is the change in a financial metric compared to the same period in the previous year, expressed as a percentage.

Insmed Incorporated Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 315.49 M, a 22.54% change year over year.
Insmed Incorporated Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 257.46 M, a 27.87% change year over year.
Insmed Incorporated Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 201.35 M, a 20.02% change year over year.
Insmed Incorporated Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 167.77 M, a 10.79% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Year-on-Year (YoY) growth	Gross Profit	Operating Income	EBIT

NasdaqGS: INSM

Insmed Incorporated

CEO	Mr. William H. Lewis J.D., M.B.A.
IPO Date	June 1, 2000
Location	United States
Headquarters	700 US Highway 202/206
Employees	1,271
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.